The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

Zynrelef sales rose 44.1 % in 2024. Heron is optimistic that the drug should record transformational growth in 2025, driven by its expanded label indications, which now cover an estimated 17 ...

Link: https://www.zacks.com/commentary/2453418/5-small-drug-stocks-to-buy-as-tariff-related-uncertainty-looms The biotech industry has been under pressure due to the ...

Zynrelef sales rose 44.1 % in 2024. Heron is optimistic that the drug should record transformational growth in 2025, driven by its expanded label indications, which now cover an estimated 17 ...

The absence of safety and efficacy data for drugs in individuals with obesity in package inserts may compromise health outcomes. Bruno Halpern, MD, PhD, a specialist in endocrinology and internal ...

"In addition to the established efficacy of CAMZYOS, these meaningful updates to the label reinforce the strong ... which were adjusted to drug interactions. This provides physicians with greater ...

Topics address small-molecule compounding; large-molecule biologic drugs are not compounded (5,6). Part one in the series addresses terminology, regulations, and labeling respective drug types.

Label updates include simplified twice-yearly ... today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 ...

which were adjusted to drug interactions. This provides physicians with greater flexibility in prescribing CAMZYOS to a broader group of eligible patients, with revised dosing and monitoring. The ...